
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxOb2dhVjB1bElMaGtyeHBOcXFwMkh5SkxpLXk2SzRydHdNSTFmbU1QX2g0a283NDBEM3Z4QVRCajVtV19QMXhrWWQ5OE1jZGxCV3hqaU5wTEtLV2huS0J1NFFON3FpX2kybjY3X3BrM3AzOWctZTRfX0dDSENPRXQ1dWJrTkRhQlctblBCdWg4MGg4Nkh5Vjh4cUU3V21jRlI3UmlFNkRYbGpuZVhjS0szdVU5bzN0S1dvVE5IY3ZBNERUdHhTWTA5S2l0akxVOXFsMkVJaEdic3dua1JfMk9BNFpTNEhVNGRhbHd3R09ieFRYRy1jN0RSOGp1dUFUMjdqdGMwRlM5cExHSmxlanFxXw?oc=5" target="_blank">Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study</a>&nbsp;&nbsp;<font color="#6f6f6f">Journal of Hematology Oncology Pharmacy</font>
